{
    "nct_id": "NCT06533579",
    "official_title": "A Phase 1/2 Safety, Dose-finding, and Pharmacokinetics Study of VNX-101 Gene Therapy in Patients with Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia",
    "inclusion_criteria": "* Age: Part 1: 18-90 years of age, Part 2: 13-90 years of age\n* Relapsed B-cell ALL with bone marrow blasts >= 5%\n* Refractory B-cell ALL as defined in the protocol\n* Bone marrow blasts requirement (flow cytometry): Part 1: >0.01% to <5% prior to VNX-101 dosing, Part 2: >0.01% to <50% prior to VNX-101 dosing.\n* Ineligible or declined CAR-T therapy or failed to respond or relapsed after such therapy\n* If prior blinatumomab treatment, cells remain CD19+ and not refractory to blinatumomab\n* AAV specified capsid total antibody <1:400\n* Protocol-specified ranges for renal, liver, cardiac and pulmonary function\n* Protocol-specified ranges for hematology parameters\nHealthy volunteers allowed\nMust have minimum age of 13 Years\nMust have maximum age of 90 Years",
    "exclusion_criteria": "* Hepatoxicity (AST or ALT > 2x upper limit of normal)\n* History of thrombotic microangiopathy or cardiomyopathy, or evidence of sensory neuropathy\n* Pregnant or nursing (lactating) women\n* Acute Graft versus Host Disease (GvHD): Grade 2-4 or chronic GvHD of any grade\n* History of hypersensitivity to corticosteroids or history of corticosteroid-related toxicity\n* Chemotherapy given within the protocol-specified discontinuation timelines\n\nOther Inclusion/Exclusion criteria to be applied per protocol.",
    "miscellaneous_criteria": ""
}